Irene Hidalgo Mayoral

Mrs. Irene Hidalgo Mayoral

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
AAANA ARTECHE
ANA ARTECHE
MRMaria José Gómez Rodríguez
Maria José Gómez Rodríguez
MCMARIA TERESA SANCHEZ CALVIN
MARIA TERESA SANCHEZ CALVIN
JQJuan Francisco Quesada-Espinosa
Juan Francisco Quesada-Espinosa
JRJose Miguel Lezana Rosales
Jose Miguel Lezana Rosales
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
Autism spectrum disorder (ASD) is a prevalent and extremely heterogeneous neurodevelopmental disorder (NDD) with a strong genetic component. In recent years, the clinical relevance of de novo mutations to the aetiology of ASD has been demonstrated. Current guidelines recommend chromosomal microarray (CMA) and a FMR1 testing as first-tier tests, but there is increasing evidence that support the use of NGS for the diagnosis of NDDs. Specifically in ASD, it has not been extensively evaluated and, thus, we performed and compared the clinical utility of CMA, FMR1 testing, and/or whole exome sequencing (WES) in a cohort of 343 ASD patients. We achieved a global diagnostic rate of 12.8% (44/343), the majority of them being characterised by WES (33/44; 75%) compared to CMA (9/44; 20.4%) or FMR1 testing (2/44; 4.5%). Taking into account the age at which genetic testing was carried out, we identified a causal genetic alteration in 22.5% (37/164) of patients over 5 years old, but only in 3.9% (7/179) of patients under this age. Our data evidence the higher diagnostic power of WES compared to CMA in the study of ASD and support the implementation of WES as a first-tier test for the genetic diagnosis of this disorder, when there is no suspicion of fragile X syndrome.

11 October 2022 in Genes
Verified
Journal Article
Open access
PDF file
Pablo Serrano-LorenzoPablo Serrano-Lorenzo
Pablo Serrano-Lorenzo
MRMaría Rabasa
María Rabasa
JEJesús Esteban
Jesús Esteban
IMIrene Hidalgo Mayoral
Irene Hidalgo Mayoral
CDCristina Domínguez-González
Cristina Domínguez-González
Miguel A. MartinMiguel A. Martin
Miguel A. Martin
Lactate dehydrogenase (LDH) catalyzes the reversible conversion of L-lactate to pyruvate. LDH-A deficiency is an autosomal recessive disorder (glycogenosis type XI, OMIM#612933) caused by mutations in the LDHA gene. We present two young adult female patients presenting with intolerance to anaerobic exercise, episodes of rhabdomyolysis, and, in one of the patients, psoriasis-like dermatitis. We identified in the LDHA gene a homozygous c.410C>A substitution that predicts a p.Ser137Ter nonsense mutation in Patient One and a compound heterozygous c.410C>A (p.Ser137Ter) and c.750G>A (p.Trp250Ter) nonsense mutation in Patient Two. The pathogenicity of the variants was demonstrated by electrophoretic separation of LDH isoenzymes. Moreover, a flat lactate curve on the forearm exercise test, along with the clinical combination of myopathy and psoriatic-like dermatitis, can also lead to the diagnosis.

15 February 2023 in Genes
Verified
Journal Article
Open access
PDF file
IMIrene Hidalgo Mayoral
Irene Hidalgo Mayoral
ASAinhoa Almeida Santiago
Ainhoa Almeida Santiago
JSJose Manuel Sánchez-Zapardiel
Jose Manuel Sánchez-Zapardiel
BCBeatriz Hidalgo Calero
Beatriz Hidalgo Calero
MHMiguel de la Hoya
Miguel de la Hoya
LRLuis Robles
Luis Robles
Hereditary breast and ovarian cancer syndrome (HBOC) is a clinical entity characterized by an increased risk of developing breast and ovarian cancer. The genetic diagnosis is based on the identification of heterozygous germinal variants in HBOC susceptibility genes. However, it has recently been described that constitutional mosaic variants can contribute to the aetiology of HBOC. In constitutional mosaicism, individuals have at least two genotypically distinct populations of cells that arise from an early post-zygote event. The mutational event occurs early enough in development to affect several tissues. It is detected in germinal genetic studies as low variant allele frequency (VAF) variants (A mosaic variant in the BRCA2 gene and propose a diagnostic algorithm to deal with potential mosaic findings identified by Next Generation Sequencing (NGS).

29 September 2025 in Clinical Genetics
Verified
Journal Article
Closed access
IMIrene Hidalgo Mayoral
Irene Hidalgo Mayoral
ACAmanda Herranz Cecilia
Amanda Herranz Cecilia
CRCarmen Rodríguez‐Jiménez
Carmen Rodríguez‐Jiménez
AÁAna Carazo Álvarez
Ana Carazo Álvarez
AMAna Bergua Martínez
Ana Bergua Martínez
SRSonia Rodríguez-Nóvoa
Sonia Rodríguez-Nóvoa

20 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
IMIrene Hidalgo Mayoral
Irene Hidalgo Mayoral
ACAmanda Herranz Cecilia
Amanda Herranz Cecilia
CRCarmen Rodríguez-Jiménez
Carmen Rodríguez-Jiménez
AÁAna Carazo Álvarez
Ana Carazo Álvarez
AMAna Bergua Martínez
Ana Bergua Martínez
SRSonia Rodríguez-Nóvoa
Sonia Rodríguez-Nóvoa
Purpose: In this study, we aimed to describe clinical, laboratory and molecular features of newborns with clinical suspicion for CTD, MCADD and VLCADD. Fatty acid β-oxidation disorders (FAODs) are a heterogenous group of inherited metabolic defects in which the main common features are fasting or stress-induce hypoketotic hypoglycemia, lactic acidemia or hyperammonemia. The implementation of newborn screening (NBS) programs based on acylcarnitine levels in dried blood spots has allowed them to change the natural course of these diseases, facilitating newborns to be referral to reference units shortly after birth to initiate preventive or therapeutical measures to improve health outcomes. However, handling NBS results is challenging and to date, no correlation between NBS acylcarnitine levels and prognosis has been conclusively established. In this context, genetics plays a key role in identifying individuals with FAODs and in correctly characterizing their disease and their risk of medical complications. Methods and results: This study included 94 newborns who were admitted between 2016 and 2023. Clinical and biochemical data were collected from hospital records. Variant analysis of 21 genes was performed using a custom targeted next generation sequencing (NGS) panel, and variants were classified according to the American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines recommendations. Molecular diagnostic was confirmed in 16/94 (17%) of newborns, and 17 novel variants were detected in in SLC22A5 , ACADM and ACADVL genes. We assessed clinical evolution of patients over time and related their clinical status and evolution to their genotype. Conclusion: In this study, we present a retrospective study of 94 newborns with clinical suspicion of CTD, MCADD and VLCADD, and provide clinical, biochemical and genotypic data. We expand the genotypic spectrum of variants in SLC22A5 , ACADM and ACADVL and highlight the role of genetics in identifying, characterizing and estimating the risk of medical complications for newborns and its impact on clinical management.

12 June 2022 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
IMIrene Hidalgo Mayoral
Irene Hidalgo Mayoral
AMAntonio Martínez-Salio
Antonio Martínez-Salio
SLSara Llamas-Velasco
Sara Llamas-Velasco
IGIrene Gómez-Manjón
Irene Gómez-Manjón
AAAna Arteche-López
Ana Arteche-López
MMMarta Moreno-García
Marta Moreno-García